Aktienanalyse zu Moderna Inc (MRNA)MRNAModerna Inc

Moderna, Inc. is a biotechnology company advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is engaged in developing medicines across infectious disease vaccines, oncology therapeutics and rare disease therapeutics. Its platform incorporates advances across three components, mRNA, delivery, and the manufacturing process, to advance its medicines. Its products are Spikevax and mNEXSPIKE (its COVID vaccines), and mRESVIA (its vaccine against respiratory syncytial virus (RSV)). It also has a diverse development pipeline that consists of 35 therapeutic and vaccine programs, six of which are in late-stage development. It has regulatory filings under review for its seasonal flu+COVID vaccine (mRNA-1083) in Europe and Canada and for its seasonal flu vaccine (mRNA-1010) in the United States, Europe, Canada and Australia. Its rare disease programs are Propionic acidemia (mRNA-3927); Methylmalonic acidemia (mRNA-3705), and Cystic Fibrosis (mRNA-3692/VX-522). It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Moderna Inc is not a good buy right now due to significant recent price volatility and negative sentiment stemming from a data leak. The current price is $200.1, with a recent drop of 25% following the leak, indicating a lack of investor confidence. Additionally, the RSI is at 37.586, suggesting that the stock is oversold, but this could be a trap given the negative catalysts. The forward P/E ratio is 23.0415, which is high considering the company's recent performance and the downgrade from several analysts, including Citi, which has a target of $80. The main risk is the ongoing insider selling, which has increased by 437.15% over the last quarter, indicating a lack of confidence from those closest to the company.